Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Bioline RX Ltd Sponsored ADR ( (BLRX) ) just unveiled an announcement.
On May 22, 2026, BioLineRx and Hemispherian announced that two abstracts on their lead candidate GLIX1 will be featured at the ASCO 2026 Annual Meeting in Chicago, underscoring rising scientific interest in this first-in-class TET2-activating small molecule. The release highlights that a first-in-human Phase 1/2a trial in glioblastoma, initiated in March 2026, is now enrolling, supported by robust preclinical data showing strong brain penetration, broad antitumor activity, favorable safety in animals, and particular relevance for high-grade gliomas with impaired TET2 activity.
The companies also reported preclinical findings that combining GLIX1 with PARP inhibitors yields synergistic cytotoxicity across diverse cancer cell lines, including tumors typically less responsive to PARP inhibition, suggesting potential to broaden the utility of PARP-targeted therapies. This mechanistic synergy and the planned Phase 2a expansion into newly diagnosed glioblastoma and select other cancers, including combinations with standard of care and PARP inhibitors, position GLIX1 as a promising new approach in a highly underserved brain tumor market and may influence future treatment paradigms for multiple solid tumors if clinical results are positive.
The most recent analyst rating on (BLRX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Bioline RX Ltd Sponsored ADR stock, see the BLRX Stock Forecast page.
Spark’s Take on BLRX Stock
According to Spark, TipRanks’ AI Analyst, BLRX is a Neutral.
The score is primarily held back by weak financial performance—especially the sharp 2025 revenue drop, ongoing losses, and negative free cash flow—despite improved cash burn and a still-positive equity base. Technicals are moderately supportive with the stock trading above key shorter-term moving averages, but mixed momentum signals and limited valuation support given negative earnings keep the overall score near the middle of the range.
To see Spark’s full report on BLRX stock, click here.
More about Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a clinical-stage biopharmaceutical company focused on oncology and rare diseases, with its lead development asset GLIX1, a first-in-class oral small molecule targeting the DNA damage response in glioblastoma and other solid tumors. The company also markets APHEXDA (motixafortide) in the U.S. for stem cell mobilization in multiple myeloma, while retaining rights to develop motixafortide in solid tumors, including metastatic pancreatic cancer, where a Phase 2b trial is ongoing. BioLineRx develops GLIX1 in collaboration with Hemispherian AS, a Norwegian clinical-stage oncology firm specializing in novel small molecule cancer therapeutics.
Average Trading Volume: 42,629
Technical Sentiment Signal: Sell
Current Market Cap: $11.65M
Learn more about BLRX stock on TipRanks’ Stock Analysis page.